Association between ipilimumab and celiac disease

Nicole M. Gentile, Anita D'Souza, Larissa L. Fujii, Tsung Teh Wu, Joseph A Murray

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial. The investigative work-up and response to a gluten-free diet essentially confirm celiac disease. Although ipilimumab-induced enterocolitis is a well-reported complication, there have been no reported cases of celiac disease with ipilimumab therapy, to our knowledge. We suspect that ipilimumab may have amplified the symptomatic presentation of previously unrecognized celiac disease or perhaps even triggered the disease itself. With ipilimumab being used more commonly in the treatment of melanoma and prostate cancer, we believe that physicians should be aware of this potential adverse outcome when evaluating a patient who experiences persistent diarrhea during or after ipilimumab treatment.

Original languageEnglish (US)
Pages (from-to)414-417
Number of pages4
JournalMayo Clinic Proceedings
Volume88
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Celiac Disease
Diarrhea
Prostatic Neoplasms
Enterocolitis
Gluten-Free Diet
Phase III Clinical Trials
Castration
Therapeutics
ipilimumab
Melanoma
Adrenal Cortex Hormones
Physicians
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association between ipilimumab and celiac disease. / Gentile, Nicole M.; D'Souza, Anita; Fujii, Larissa L.; Wu, Tsung Teh; Murray, Joseph A.

In: Mayo Clinic Proceedings, Vol. 88, No. 4, 2013, p. 414-417.

Research output: Contribution to journalArticle

Gentile, Nicole M. ; D'Souza, Anita ; Fujii, Larissa L. ; Wu, Tsung Teh ; Murray, Joseph A. / Association between ipilimumab and celiac disease. In: Mayo Clinic Proceedings. 2013 ; Vol. 88, No. 4. pp. 414-417.
@article{078e365541894f888b8d6f65d2c8b539,
title = "Association between ipilimumab and celiac disease",
abstract = "A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial. The investigative work-up and response to a gluten-free diet essentially confirm celiac disease. Although ipilimumab-induced enterocolitis is a well-reported complication, there have been no reported cases of celiac disease with ipilimumab therapy, to our knowledge. We suspect that ipilimumab may have amplified the symptomatic presentation of previously unrecognized celiac disease or perhaps even triggered the disease itself. With ipilimumab being used more commonly in the treatment of melanoma and prostate cancer, we believe that physicians should be aware of this potential adverse outcome when evaluating a patient who experiences persistent diarrhea during or after ipilimumab treatment.",
author = "Gentile, {Nicole M.} and Anita D'Souza and Fujii, {Larissa L.} and Wu, {Tsung Teh} and Murray, {Joseph A}",
year = "2013",
doi = "10.1016/j.mayocp.2013.01.015",
language = "English (US)",
volume = "88",
pages = "414--417",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Association between ipilimumab and celiac disease

AU - Gentile, Nicole M.

AU - D'Souza, Anita

AU - Fujii, Larissa L.

AU - Wu, Tsung Teh

AU - Murray, Joseph A

PY - 2013

Y1 - 2013

N2 - A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial. The investigative work-up and response to a gluten-free diet essentially confirm celiac disease. Although ipilimumab-induced enterocolitis is a well-reported complication, there have been no reported cases of celiac disease with ipilimumab therapy, to our knowledge. We suspect that ipilimumab may have amplified the symptomatic presentation of previously unrecognized celiac disease or perhaps even triggered the disease itself. With ipilimumab being used more commonly in the treatment of melanoma and prostate cancer, we believe that physicians should be aware of this potential adverse outcome when evaluating a patient who experiences persistent diarrhea during or after ipilimumab treatment.

AB - A 62-year-old man with chemotherapy-naive, castration-resistant metastatic prostate cancer presented with refractory diarrhea despite prolonged high-dose corticosteroid treatment after receiving 3 doses of ipilimumab as part of a phase 3 clinical trial. The investigative work-up and response to a gluten-free diet essentially confirm celiac disease. Although ipilimumab-induced enterocolitis is a well-reported complication, there have been no reported cases of celiac disease with ipilimumab therapy, to our knowledge. We suspect that ipilimumab may have amplified the symptomatic presentation of previously unrecognized celiac disease or perhaps even triggered the disease itself. With ipilimumab being used more commonly in the treatment of melanoma and prostate cancer, we believe that physicians should be aware of this potential adverse outcome when evaluating a patient who experiences persistent diarrhea during or after ipilimumab treatment.

UR - http://www.scopus.com/inward/record.url?scp=84876563528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876563528&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2013.01.015

DO - 10.1016/j.mayocp.2013.01.015

M3 - Article

C2 - 23541015

AN - SCOPUS:84876563528

VL - 88

SP - 414

EP - 417

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -